Bioavailability Study
Conditions
Keywords
MP29-02
Brief summary
The aim of this study is to investigate and to compare the bioavailability of MP29-02 and fluticasone propionate in nasal tissue after nasal application. This may provide a rational basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has demonstrated the efficacy of the twice-daily treatment; however, so far, no data are available on the local tissue concentrations of MP29-02 after topical application.
Detailed description
The study will be a single-centre, two-treatment half-side comparative open-label trial; all subjects will receive Dymista® or Flixonase Aqua in one nostril each. Nasal tissue samples will be obtained from 24 patients. Subjects will be selected based on the subjects plan to undergo septoplasty, septorhinoplasty, or functional endoscopic sinus surgery. Subjects with different diagnoses can be added in the study: non-allergic rhinitis, allergic rhinits, chronic sinusitis and nasal polyposis. The number of subjects is based on a previous experiment where the presence of fluticasone propionate was tested on human nasal mucosal surface and in human nasal tissue after nasal application (Bonsmann, 2001).
Interventions
DRUGMP29-02
local nasal application
DRUGFluticasone propionate
local nasal application
Sponsors
MEDA Pharma GmbH & Co. KG
University of Wuerzburg
University Hospital, Ghent
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* \- Male and female patients * Age: 18 - 70 years (included) * Subjects who need to undergo septoplasty, septorhinoplasty or functional endoscopic sinus surgery unrelated to this study * Willing and able to provide informed consent
Exclusion criteria
* \- Patients who are member of the staff or relatives thereof directly involved in the conduct of the protocol * Participant in any other trial during the last 30 days * Previous treatment with Dymista or any other topical corticosteroid spray or drops within the last month before the operation * Previous treatment with systemic corticosteroid in the last 2 months before operation * Previous treatment with anti-histaminics 7 days before operation * Pregnant or breast feeding women * Allergic for one of the compounds azelastinehydrochloride or fluticasonpropionate * Significant co-morbidity (for instance, but not limited to): * Glaucoma, cataracts, and increased intraocular pressure. * Subjects with active or quiescent tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex * Subjects with severe liver disease * Use of prohibited concomitant medication * Potent inhibitors of cytochrome P450 (CYP) 3A4 * Ritonavir * Patients unwilling or unable to attend the proposed visit schedule * Patients suspected or known not to be trustworthy or who are likely not to comply with the study directives
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| bioavailability of MP29-02 in human nasal mucosa compared to commercially available fluticasone propionate | 1 hour | bioavailability of both medicines will be tested in nasal mucosa and nasal secretion 1 after application |
Countries
Belgium
Outcome results
None listed